just listened to the recording...three pages of sc
Post# of 2146
Posted On: 08/05/2013 3:12:48 PM
just listened to the recording...three pages of scribbled notes!
Some thoughts
- They are prioritizing two of the newly acquired ANDA's. Specifically going after small markets with only one generic competitor. The Loxapine is a very small market, about $20,000,000. The three listed manufacturers are Activas, Watson and Mylan. Now Actavis and Watson are one and the same and of course the had to divest Loxapine. So it's now Elite and Mylan splitting a $20,000,000 market. So this could easily become a $4,000,000 drug. The other one if I had to guess is Dantrolene Sodium. The four listed manufacturers are: Actavis, Impax, JHP and US WorldMeds. But I'm not really sure on this one. The "big fish/small pond" strategy is perfect.
- I'd like to be Nasrat's real estate agent...
- Clinical trials start in November, Nasrats estimation. So results could come in what 3-4 months after?
- The shift to ART development being the biggest company priority is significant. JT righted the ship, got financing, got cashflow from generics and now we are ready for the next leg up.
- MIK001 deal remains with Mikah, which continues to exist.
- We have full title now to Phendimetrazine so will accelerate profitability and sales here.
- Mikah previously only marketed Phendimetrazine to clinics, now Elite can expand that market
- They have already met with potential marketing partner for this basket of drugs.
- They are resource limited so again watch for aggressive push on two of the new ANDA's with the rest back burnered for a bit.
- I was impressed by the number of callers given the short notice on the call.
- Nasrats desire/plan is to be back on NASDAQ in 2 years.
- We have another CC next week. Positive earnings and maybe naltrexone launch?
Some thoughts
- They are prioritizing two of the newly acquired ANDA's. Specifically going after small markets with only one generic competitor. The Loxapine is a very small market, about $20,000,000. The three listed manufacturers are Activas, Watson and Mylan. Now Actavis and Watson are one and the same and of course the had to divest Loxapine. So it's now Elite and Mylan splitting a $20,000,000 market. So this could easily become a $4,000,000 drug. The other one if I had to guess is Dantrolene Sodium. The four listed manufacturers are: Actavis, Impax, JHP and US WorldMeds. But I'm not really sure on this one. The "big fish/small pond" strategy is perfect.
- I'd like to be Nasrat's real estate agent...
- Clinical trials start in November, Nasrats estimation. So results could come in what 3-4 months after?
- The shift to ART development being the biggest company priority is significant. JT righted the ship, got financing, got cashflow from generics and now we are ready for the next leg up.
- MIK001 deal remains with Mikah, which continues to exist.
- We have full title now to Phendimetrazine so will accelerate profitability and sales here.
- Mikah previously only marketed Phendimetrazine to clinics, now Elite can expand that market
- They have already met with potential marketing partner for this basket of drugs.
- They are resource limited so again watch for aggressive push on two of the new ANDA's with the rest back burnered for a bit.
- I was impressed by the number of callers given the short notice on the call.
- Nasrats desire/plan is to be back on NASDAQ in 2 years.
- We have another CC next week. Positive earnings and maybe naltrexone launch?
(0)
(0)